| |
In silico trials are emerging as an alternative to randomized controlled trials for rare diseases, particularly where no standard of care exists, or placebo is unethical. Download our whitepaper to learn more about this transformative approach.
|
|
Today’s Big NewsNov 12, 2024 |
| By James Waldron Months after filing their Enhertu follow-up Dato-DXd with the FDA, Daiichi Sankyo and its antibody-drug conjugate partner AstraZeneca have taken the agency’s advice and pulled their lung cancer application to try their luck in a related indication. |
|
|
|
By Gabrielle Masson GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that includes a preclinical small molecule initially targeting Parkinson’s disease. |
By James Waldron Bayer has become the latest in a long line of drug developers to give up on Huntington’s disease after the German pharma giant canned its phase 1 gene therapy for the disease. |
Sponsored by IO Biotech Making the tumor microenvironment hostile to cancer cells and immune-suppressive cells may transform the cancer treatment landscape. |
|
Experience how our CMC and regulatory capabilities help achieve seamless, timely launches. Give your molecule the best chance of success. Start today.
|
|
By Nick Paul Taylor Merck KGaA’s $70 million bet on a treatment for a rare, locally aggressive cancer has delivered a phase 3 win. The tenosynovial giant cell tumor trial hit its primary endpoint, teeing up an option decision that could establish Merck as a global rival to Daiichi Sankyo and Ono Pharmaceutical in the indication. |
By James Waldron With Pfizer having recently scored an approval for its hemophilia B treatment Hympavzi, Centessa Pharmaceuticals has decided that taking its own contender to market is not worth the effort. |
By Nick Paul Taylor Novartis is paying $150 million for a closer look at Schrödinger’s catalog of programs. The Big Pharma will work with Schrödinger to advance some of the computing-enabled R&D shop’s discovery programs and identify candidates against additional targets. |
By Gabrielle Masson Roche and Flare Therapeutics are igniting a partnership worth more than $1.8 billion in biobucks with hopes of discovering new small molecule cancer treatments via previously undruggable transcription factor targets. |
By Gabrielle Masson Swiss biotech Alentis Therapeutics has secured $181.4 million, money that will be used to launch clinical trials for two antibody-drug conjugates. |
By James Waldron Trace Medicine has launched with $101 million in series A funds and a mission to treat amyotrophic lateral sclerosis (ALS) by targeting the same protein that recently caught the attention of Eli Lilly. |
By Gabrielle Masson With more than $80 million in hand, the University of Texas MD Anderson Cancer Center has launched its own cell therapy institute. |
By Conor Hale The genetics testing company plans to seek out new homes for its in-house pipeline of DNA-informed immuno-oncology antibodies. |
By Fraiser Kansteiner AstraZeneca on Tuesday revealed that it’s adding $2 billion more to its current outlay in the U.S., representing a total capital investment of $3.5 billion. The cash will be used to grow the company’s research and production footprint in the States by the end of 2026, generating more than 1,000 new jobs along the way. |
By Anastassia Gliadkovskaya Though women's health providers also saw a jump in sales following the overturning of Roe v. Wade, many say the latest surge exceeds previous numbers. |
By Fraiser Kansteiner Thermo Fisher is cutting a total of 160 jobs across three different viral vector facilities in Cambridge, Lexington and Plainville, according to a government filing in Massachusetts. In tandem with the staff reduction, Thermo Fisher also plans to shutter its facility in Lexington. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," we take a closer look at this year’s biotech graveyard, which tracks biotechs that have closed or are winding down. |
|
|---|
|
|
| WhitepaperThe use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
| WhitepaperExplore the robust cross-platform agreement between scRNA-seq and bulk RNA-seq, ensuring consistent and reproducible data on immune cell presence. Sponsored by: IQVIA Laboratories |
| WhitepaperThis e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development. Sponsored by: Blue Matter |
| WhitepaperUnlock the secrets to faster, cost-effective biologics production with intensified biomanufacturing – download the whitepaper and power up your bioprocessing game! Sponsored by: Syngene International Ltd. |
| WhitepaperDiscover how independent adjudication can safeguard your clinical trials from misidentified adverse events and enhance the credibility of your results. Sponsored by: WCG |
| WhitepaperLearn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
